Clasp Therapeutics’ novel T cell engagers could offer advantages over others in this class of cancer immunotherapies. The startup is based on the research of Johns Hopkins University scientist Bert Vogelstein.
AbbVie will take the lead on commercializing Regenxbio’s gene therapy in wet AMD and diabetic retinopathy. It’s AbbVie’s second major gene therapy deal this year, coming months after it committed $90 million to preclinical-stage Capsida Biotherapeutics.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
FDA approval of Supernus Pharmaceuticals drug Qelbree gives attention-deficit hyperactivity disorder patients another treatment option that is not classified as a Schedule II substance. It’s a different formulation of a drug that was first approved in Europe decades ago.
Pfizer, which had been running the trial of rivipansel in SCD, reported that it had failed on its primary and key secondary endpoints.
In a conference call with analysts, the company's CEO was tight-lipped about the median improvement in PFS, but the results nevertheless beat many investors' expectations.
Two trials involving the drug MGD009 - a monotherapy study and one in combination with the company's PD-1 inhibitor - are barred from enrolling new patients pending FDA review and a planned protocol amendment.
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
A new analysis from Rockville, Maryland-based Cryptonite found that ransomware is on the rise. While there were 19 healthcare ransomware events reported to HHS/OCR in 2016, there were 36 in 2017.
Abilify MyCite, developed in collaboration between Proteus Digital Health and Otsuka Pharmaceutical, has an ingestible sensor embedded in the pill which records that the medication was taken. It reflects a trend by companies to use sensors to quantify the effectiveness of medications.
Among the technologies in Relevant Health's seven-member inaugural class are wearables to reduce back injury risk and reducing seniors' fall risk.
In exchange for a $50,000 investment, Relevant Health takes up to an 8 percent equity stake.
We will highlight Build My Health's revenue practice management tools, which could help physician practices add up to $250,000 to their practices.
Hospitals are improving their patient safety track record, particularly when it comes to reducing the pressure ulcers that can result in complications like infections and lengthened hospital stays. A report released this week by Agency for Healthcare Research and Quality showed a 17 percent decline in hospital-acquired conditions from 2010 to 2013. Last year alone, […]